Childhood Mortality After Mass Distribution of Azithromycin: A Secondary Analysis of the PRET Cluster-randomized Trial in Niger
- PMID: 29561511
- PMCID: PMC6138579
- DOI: 10.1097/INF.0000000000001992
Childhood Mortality After Mass Distribution of Azithromycin: A Secondary Analysis of the PRET Cluster-randomized Trial in Niger
Abstract
Background: Mass distributions of azithromycin for trachoma have been associated with secondary benefits, including reductions in child mortality.
Methods: In the Partnership for the Rapid Elimination of Trachoma cluster-randomized trial in Niger, 24 communities were randomized to annual treatment of everyone and 24 communities were randomized to biannual treatment of children under 12 for 3 years (clinicaltrials.gov, NCT00792922). Treatment was a single dose of directly observed oral azithromycin (20 mg/kg up to 1 g in adults). Vital status was assessed during annual census and monitoring visits. In this prespecified secondary analysis, we compared the mortality rate among children 6 months to less than 5 years of age by treatment arm using negative binomial regression.
Results: Among children 6 months to less than 5 years of age, 404 deaths occurred during the study period. The mortality rate was 35.6 deaths per 1000 person-years (231 deaths, 95% CI: 30.9-40.9) in the annual arm and 29.0 deaths per 1000 person-years (173 deaths, 95% CI: 24.8-33.8) in the biannual arm. The mortality rate ratio comparing children in the biannual arm to the annual arm was 0.81 (95% CI: 0.66-1.00, P = 0.07; primary outcome). The mortality rate ratio comparing children who died from infectious causes in the biannual arm to the annual arm was 0.73 (95% CI: 0.57-0.94; P = 0.02). No adverse events were reported.
Conclusions: This secondary analysis of a cluster-randomized trial found a nonsignificant 19% decrease in mortality among children 6 months to less than 5 years of age who received biannual azithromycin compared with children who received annual azithromycin. This study was conducted in a high mortality, trachoma-endemic area; thus, results may be specific to this environment only. In addition, the trial was neither designed nor powered to detect a mortality effect, and we cannot rule out the possibility that mortality differences resulted from bias.
Conflict of interest statement
No conflicts of interest exist and none of the authors have any disclosures.
Figures
Similar articles
-
Biannual versus annual mass azithromycin distribution and malaria seroepidemiology among preschool children in Niger: a sub-study of a cluster randomized trial.Malar J. 2019 Dec 3;18(1):389. doi: 10.1186/s12936-019-3033-2. Malar J. 2019. PMID: 31796025 Free PMC article.
-
Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial.JAMA. 2009 Sep 2;302(9):962-8. doi: 10.1001/jama.2009.1266. JAMA. 2009. PMID: 19724043 Clinical Trial.
-
Cause-specific mortality of children younger than 5 years in communities receiving biannual mass azithromycin treatment in Niger: verbal autopsy results from a cluster-randomised controlled trial.Lancet Glob Health. 2020 Feb;8(2):e288-e295. doi: 10.1016/S2214-109X(19)30540-6. Lancet Glob Health. 2020. PMID: 31981558 Free PMC article. Clinical Trial.
-
Biannual azithromycin mass drug administration for reduction of childhood mortality: a systematic review and meta-analysis.J Antimicrob Chemother. 2025 May 2;80(5):1197-1206. doi: 10.1093/jac/dkaf092. J Antimicrob Chemother. 2025. PMID: 40129224
-
One drug to treat them all: ethical implications of the MORDOR trial of mass antibiotic administration to reduce child mortality.J Glob Health. 2019 Jun;9(1):010305. doi: 10.7189/jogh.09.010305. J Glob Health. 2019. PMID: 30643634 Free PMC article. Review. No abstract available.
Cited by
-
Age-based targeting of biannual azithromycin distribution for child survival in Niger: an adaptive cluster-randomized trial protocol (AVENIR).BMC Public Health. 2021 Apr 29;21(1):822. doi: 10.1186/s12889-021-10824-7. BMC Public Health. 2021. PMID: 33926403 Free PMC article.
-
Efficacy of Mass Azithromycin Distribution for Reducing Childhood Mortality Across Geographic Regions.Am J Trop Med Hyg. 2020 Sep;103(3):1291-1294. doi: 10.4269/ajtmh.18-1003. Am J Trop Med Hyg. 2020. PMID: 30734695 Free PMC article.
-
Safety of azithromycin in pediatrics: a systematic review and meta-analysis.Eur J Clin Pharmacol. 2020 Dec;76(12):1709-1721. doi: 10.1007/s00228-020-02956-3. Epub 2020 Jul 17. Eur J Clin Pharmacol. 2020. PMID: 32681202 Free PMC article.
-
Safety of azithromycin in infants under six months of age in Niger: A community randomized trial.PLoS Negl Trop Dis. 2018 Nov 12;12(11):e0006950. doi: 10.1371/journal.pntd.0006950. eCollection 2018 Nov. PLoS Negl Trop Dis. 2018. PMID: 30419040 Free PMC article. Clinical Trial.
-
Single-dose azithromycin for child growth in Burkina Faso: a randomized controlled trial.BMC Pediatr. 2021 Mar 17;21(1):130. doi: 10.1186/s12887-021-02601-7. BMC Pediatr. 2021. PMID: 33731058 Free PMC article. Clinical Trial.
References
-
- Evans JR, Solomon AW. Antibiotics for trachoma. Cochrane Database Syst Rev. 2011 Cd001860. - PubMed
-
- Coles CL, Levens J, Seidman JC, Mkocha H, Munoz B, West S. Mass distribution of azithromycin for trachoma control is associated with short-term reduction in risk of acute lower respiratory infection in young children. Pediatr Infect Dis J. 2012;31:341–346. - PubMed
-
- Fry AM, Jha HC, Lietman TM, et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin Infect Dis. 2002;35:395–402. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical